Patent details

301080 Product Name: indacaterolacetaat of indacaterolxinafoaat, bij voorkeur indacaterolacetaat, in combinatie met mometasonfuroaat en glycopyrronium

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301080
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2044025
Status:
Application Pending
Application number:
301080
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)

Marketing Authorization

1

Marketing Authorization Number:
EU/1/20/1440
Marketing Authorization Type:
EEA
Marketing Authorization Date:
06/07/2020
Marketing Authorization Country:
European Union (EU)

2

Marketing Authorization Number:
EU/1/20/1438
Marketing Authorization Type:
EEA
Marketing Authorization Date:
06/07/2020
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
16/12/2020
First Marketing Authorization date:
06/07/2020
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
17/12/2020
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
16/12/2020
 
 

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, BASEL, Switzerland (CH)

Agent

1

Name:
ir. B.Ch. Ledeboer c.s
From:
09/01/2025
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

2

Name:
ir. H.A. Witmans c.s.
From:
16/12/2020
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
09/01/2025

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
52/20
Publication date:
23/12/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
17/12/2020 Outgoing Correspondence Confirmation receipt request 1 PDF /4/2/2/5/3/0800635224/docs/301080_12_384939l174.pdf
16/12/2020 SPC Documents Annex SPC 29 PDF /4/2/2/5/3/0800635224/docs/301080_0_supplprotectioncertificate20201217101658988.pdf
16/12/2020 SPC Documents Annex SPC 28 PDF /4/2/2/5/3/0800635224/docs/301080_1_supplprotectioncertificate20201217102028756.pdf
16/12/2020 Application Form First filed application form 3 PDF /4/2/2/5/3/0800635224/docs/301080_2_applicationform20201217095708235.pdf
16/12/2020 SPC Documents Accompanying letter SPC 3 PDF /4/2/2/5/3/0800635224/docs/301080_3_supplprotectioncertificate20201217100144697.pdf
16/12/2020 SPC Documents Annex SPC 2 PDF /4/2/2/5/3/0800635224/docs/301080_4_supplprotectioncertificate20201217101909913.pdf
16/12/2020 SPC Documents Annex SPC 10 PDF /4/2/2/5/3/0800635224/docs/301080_5_supplprotectioncertificate20201217101058858.pdf
16/12/2020 SPC Documents Marketing Authorization SPC 3 PDF /4/2/2/5/3/0800635224/docs/301080_6_supplprotectioncertificate20201217100305697.pdf
16/12/2020 SPC Documents Summary of the characteristics of the product 25 PDF /4/2/2/5/3/0800635224/docs/301080_7_supplprotectioncertificate20201217101248774.pdf
16/12/2020 SPC Documents Annex SPC 2 PDF /4/2/2/5/3/0800635224/docs/301080_8_supplprotectioncertificate20201217100752001.pdf
16/12/2020 SPC Documents Annex SPC 2 PDF /4/2/2/5/3/0800635224/docs/301080_9_supplprotectioncertificate20201217101501435.pdf
16/12/2020 SPC Documents Summary of the characteristics of the product 25 PDF /4/2/2/5/3/0800635224/docs/301080_10_supplprotectioncertificate20201217101816552.pdf
16/12/2020 SPC Documents Marketing Authorization SPC 3 PDF /4/2/2/5/3/0800635224/docs/301080_11_supplprotectioncertificate20201217100638899.pdf